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Abstract
Background: Current vector-based malaria control strategies are threatened by the rise of biochemical and behavioural
resistance in mosquitoes. Researching mosquito traits of immunity and fertility is required to find potential targets for new
vector control strategies. The seminal transglutaminase AgTG3 coagulates male Anopheles gambiae seminal fluids, forming
a ‘mating plug’ that is required for male reproductive success. Inhibitors of AgTG3 can be useful both as chemical probes
of A. gambiae reproductive biology and may further the development of new chemosterilants for mosquito population
control.
Methods: A targeted library of 3-bromo-4,5-dihydroxoisoxazole inhibitors were synthesized and screened for inhibition of
AgTG3 in a fluorescent, plate-based assay. Positive hits were tested for in vitro activity using cross-linking and mass
spectrometry, and in vivo efficacy in laboratory mating assays.
Results: A targeted chemical library was screened for inhibition of AgTG3 in a fluorescent plate-based assay using its
native substrate, plugin. Several inhibitors were identified with IC50<10μM. Preliminary structure-activity relationships
within the library support the stereo-specificity and preference for aromatic substituents in the chemical scaffold.
Both inhibition of plugin cross-linking and covalent modification of the active site cysteine of AgTG3 were verified.
Administration of an AgTG3 inhibitor to A. gambiae males by intrathoracic injection led to a 15% reduction in mating
plug transfer in laboratory mating assays.
Conclusions: A targeted screen has identified chemical inhibitors of A. gambiae transglutaminase 3 (AgTG3). The most
potent inhibitors are known inhibitors of human transglutaminase 2, suggesting a common binding pose may exist
within the active site of both enzymes. Future efforts to develop additional inhibitors will provide chemical tools to
address important biological questions regarding the role of the A. gambiae mating plug. A second use for
transglutaminase inhibitors exists for the study of haemolymph coagulation and immune responses to wound healing
in insects.
Background
Both historically and at present, vector control remains
the most generally effective measure to prevent malaria
transmission [1]. The two major control measures pres-
ently used are insecticide indoor residual spraying (IRS)
and insecticide-treated bed nets (ITN). Both measures
effectively target Anopheles gambiae, the principal mal-
aria vector in sub-Saharan Africa, as it is both endophilic
and endophagic. Yet IRS/ITN can be hindered by the se-
lection of both biochemical and behavioural resistance in
mosquitoes, driven by the same potent and rapid toxicity
for which the insecticides are designed. Hence, while IRS/
ITN will hopefully be successful in controlling and elimin-
ating malaria, additional tools may be required to achieve
the long-term goal of malaria eradication.
The sterile insect technique (SIT) is an alternative ap-
proach to insect control that has been successfully de-
ployed against both agricultural pests and disease vectors
[2-5], but never Anopheles mosquitoes. Classic SIT in-
volves the mass release of sterile males, which for mosqui-
toes carries no disease risk because only females blood
feed. Three methods of inducing sterility in males have
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[6], chemosterilization [7-9], and genetic modification
(GM) [10-13]. Despite its feasibility, the deployment of
SIT for malaria control has been hindered by (i) logis-
tical costs of gamma irradiation due to loss of fitness
[14-16], (ii) perceived hazards associated with non-
specific chemosterilants [17], and (iii) regulatory con-
cerns with genetic modification [18-20].
Chemosterilization has generally delivered improved
fitness compared to gamma irradiation [17], motivating
a search for more specific and less toxic chemical agents
to reduce the fertility of mosquitoes. To be applicable in
the field a chemosterilant must meet the same efficiency
and safety standards required from approved insecticides,
it must not kill mosquitoes at the dose delivered nor
change their mating behaviour, and if the compound is
toxic or otherwise hazardous to the environment the re-
leased insect must be free of or contain a minimal residue
of it [21]. The chitinase inhibitor luferunon, a benzoylurea
derivative found in common flea control medications, has
been successfully used as an edible bait for sterile control
of fruit flies and related pests [22-24]. The DNA alkylating
agent bisazir (P,P-bis(aziridin-1-yl)-N-methylphosphi-
nothioic amide) was successfully used to chemosterilize
Anopheles albimanus in field trials [25-28], but concerns
over residual effects in non-target species [29] and poten-
tial health/environmental hazard limited operational
deployment.
Hence, chemosterilants with improved specificity or a
lower environmental hazard profile compared with bisazir
could potentially advance the use of SIT in mosquitoes.
The discovery of new chemosterilants would be enhanced
by a better understanding of mosquito mating biology, in-
cluding the function of numerous proteins of unknown
function found in male seminal fluids. This goal would be
advanced by identifying potential compounds targeting a
specific enzyme within male seminal fluids that disrupts or
inhibits the fertility of A. gambiae.T h ef i r s tt a r g e to fi n t e r -
est identified was the male-specific protein AGAP009099,
A. gambiae transglutaminase 3 (AgTG3).
Transglutaminases (TGs) catalyze the deamidation and
transamidation of glutamine and the cross-linking of pro-
teins by formation of ε-(γ-glutamyl)-lysine isopeptide
bonds [30]. In mammals TGs are involved in blood clot-
ting, formation of the epidermal barrier, cross-linking of
the extracellular matrix, coagulation of seminal fluids, and
contribute to the pathophysiology of cancer, inflammatory,
autoimmune, and neurodegenerative diseases [31-33]. Of
the eight active TGs in humans, tissue TG (hTG2) and
blood clotting factor XIII (fXIIIa) have been the target of
drug development for the treatment of disease. TGs are
Ca2+−activated enzymes that rely on an active site cyst-
eine to catalyze transamidation via a ‘ping-pong’ mechan-
ism, in which the sulfhydryl attacks the glutamine group
forming an acyl intermediate that is substituted by lysine
(Figure 1A). The majority of TG inhibitors are tight, slow-
binding inhibitors that react with the active site cysteine
to irreversibly inhibit the enzyme [34].
Drosophila melanogaster has a single TG (DmTG) in-
volved in cuticle morphogenesis and the coagulation of
haemolymph in response to septic injury [35-37]. This TG
is conserved in mosquitoes (A. gambiae AGAP009100, or
AgTG1). Culex and Anopheles mosquitoes share a second
TG gene (A. gambiae AGAP009098, or AgTG2), which
has recently been implicated in the immune response to
Plasmodium falciparum [38]. Anopheles gambiae has a
third, male-specific TG, AgTG3, that coagulates male
seminal fluids to form a ‘mating plug’ required for male
reproductive success [39,40]. AgTG3 represents a specific,
validated target for reducing male fertility in comparison
to other broad-spectrum chemosterilants tested in mos-
quitoes. While there is some debate as to whether an in-
hibitor of AgTG3 would be an effective chemosterilant
[40,41], an inhibitor of AgTG3 can be used as a chemical
probe to analyse the role of the mating plug in the repro-
ductive biology of A. gambiae and other seminal fluid pro-
teins of unknown function.
Figure 1 Chemical mechanism of transglutaminase and DHI
inhibitors. (A) Mechanism of transglutaminase isopeptide bond
formation. (B) Structure of acivicin, S-DHI-derived
transglutaminase inhibitors.
Le et al. Malaria Journal 2014, 13:210 Page 2 of 12
http://www.malariajournal.com/content/13/1/210The in vitro characterization of AgTG3 and cross-
linking of its native substrate plugin have been previously
reported [42]. Using a C-terminal fragment of plugin and
fluorescein-cadaverine (FITC-CAD), a plate-based fluor-
escent assay was established and used to assay the ac-
tivity of AgTG3 and inhibition by the halomethyl
ketone iodoacetamide (IA), a potent but non-specific in-
hibitor of cysteine proteases and TGs. Besides iodoaceta-
mide, a wide range of more specific halomethyl ketones.
3-halo-dihydroisoxazoles (DHIs), sulfonium methyl ke-
tones (incl. thioimidazolium derivatives), epoxides, 1,2,4-
thiadiazoles, diazomethyl ketones, maleimides and acryloyl
amides (Michael acceptors) have been developed as TG
inhibitors [34], Through synthesis, screening and SAR, TG
inhibitors with IC50<100 nM and specificity for TG2 over
fXIIIa have been developed [43,44].
DHI derivatives are based on the natural antibiotic acivi-
cin (Figure 1B). Acivicin is non-toxic to Drosophila deliv-
ered orally ad libitum (10 μM in agar) and was active
in vivo in a tumor model [45], while 3-bromoacivicin dis-
played no acute toxicity in mice at 50 mg/kg (intraperito-
neal injection) and was active in vivo in a model of human
African trypanosomiasis [46]. A series of DHI-based TG
inhibitors synthesized and screened for activity against hu-
man TG2 [47-53] resulted in compounds that were toler-
ated at doses of 50 mg/kg via intraperitoneal injections in
mice and were efficacious in blocking TG2 activity in vivo
[51]. These studies suggest DHIs as a chemical class fulfill
the criteria for compounds suitable as in vivo chemical
probes or chemosterilants with an improved hazard profile
compared to previously tested chemosterilants, such as
bisazir.
Here, the assembly of a targeted chemical library of DHI
and other TG inhibitors is reported, including previously
characterized inhibitors of hTG2. Upon screening the li-
brary for inhibition of AgTG3 in the previously described
FITC-CAD assay, several compounds were identified as po-
tential inhibitors. These results were supported by dose–re-
sponse experiments to determine the IC50 for a subset of
structurally related compounds within the library. Inhib-
ition of AgTG3 by the most active inhibitors was further
validated in vitro. Injection of a DHI inhibitor into adult
male A. gambiae provided a comparable effect to RNAi-
mediated knock-down of AgTG3 in preventing transfer of
t h em a t i n gp l u g .T h e s er e s u l t sa r eap r o o f - o f - p r i n c i p l ef o r
the development of new classes of chemosterilants by mo-
lecular analysis of the reproductive biology of mosquitoes,
and the use of TG inhibitors targeting both fertility and im-
munity in insects.
Methods
Library design and synthesis
The targeted library consisted of 92 compounds: 83 of
the DHI chemotype and nine of alternate chemotypes.
The DHI compounds were composed of previously re-
ported hTG2 inhibitors [49-51,53], with additional unpub-
lished derivatives (Additional file 1: Chemical Synthesis
and Additional file 2: Table S1). The compound scaffold is
an amino acid with an N-terminal protecting group and
the DHI warhead attached to the C-terminus by an amide
bond (Figure 1C). Alanine, aspartic and glutamic acid
were present but the library was biased to L- and D- cyc-
lic/aromatic residues and derivatives thereof. N-terminal
protecting groups were biased towards aromatic methyl
carbamates with several ethyl, t-butyl carbamates and two
amides present. Initial compounds were racemic mixtures
of (S/R)-DHI. As hTG2 is selectively inhibited by (S)-DHI,
however, only 26 compounds in the library were race-
mates, another eight contained R-DHI and 49 were S-
DHI. Besides DHI inhibitors, the library contained eight
acylidene oxoindoles and the thienopyrimidinone LDN-
27219 [54,55]. Acylidene oxoindoles are reversible, slow
tight-binding inhibitors of hTG2 [55]; the thienopyrimidi-
nones are allosteric inhibitors [54,56]. The binding site on
TG2 is unknown for either chemotype.
The DHI inhibitors were prepared according to the syn-
thetic routes outlined in Figure 2. In one previously pub-
lished sequence (route A), the amino acid methyl ester
(free base or hydrochloride) is decorated with the desired
carbamate substituent by reacting it with the respective 4-
nitrophenyl carbonate building block. After saponification
of the ester with aqueous lithium hydroxide, the (S)-DHI
moiety can be introduced via standard amide coupling
chemistry, furnishing the final inhibitor [49,50]. Recently,
the reaction sequence was inverted (route B) to use the
commercial abundance of BOC precursors [53]. Coupling
of the BOC amino acid to the (S)-DHI moiety followed by
BOC deprotection with TFA furnished an intermediate
that could be directly coupled to the carbonate building
block without further purification. The individual carbon-
ate and (S)-DHI building blocks were prepared as previ-
ously published [47,50,57].
Figure 2 Synthetic routes to generate DHI inhibitor library.
(A) Route for synthesis of previously reported DHI inhibitors.
(B) Inverted route to utilize commercial BOC derivatives of amino acids.
(a) 4-nitrophenyl carbonate, N-methylmorpholine, CH2Cl2, RT, overnight;
( b )L i O H( 1e q . )M e O H / T H F ;( c )( S)-DHI, EDCI, HOBt, DMF; (d) TFA.
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Plugin-C (25 μg/well) was incubated in black 96-well Ni-
coated plates (Pierce 15342) for 2 h at room temperature or
overnight at 4°C. Plates were washed three times with
200 μLo fT B Sa n dl o a d e dw i t h0 . 5μgo fA g T G 3i n5 0μL
TBS buffer. DHI inhibitors were added for 1 h to block the
enzyme, followed by 50 μL of 2× assay buffer (2× TBS,
20 mM CaCl2, 100 μM FITC-CAD, 2 mM DTT). Wells
were incubated for 60 min at room temperature, washed
three times with 200 μL of TBS, and filled to a final volume
of 100 μL for fluorescence measurements in a microplate
reader (Biotek Synergy 2). The z-score was calculated based
on the mean and standard deviation of three replicates of
inhibitor compared to a DMSO control, zi ¼  xDMSO− xi jj =
σDMSO þ σi ðÞ .
AgTG3 plugin cross-linking assay
Recombinant AgTG3 was pre-incubated with 100 μMi n -
hibitors overnight at room temperature. AgTG3, with and
without pretreatment with inhibitors (1 μg), was added to
plugin-C (20 μg) and 0.5 mM FITC-cadaverine (FITC-
CAD) in 25 mM HEPES, pH 7.5, 10 mM CaCl2,1m M
DTT. The reaction was incubated at room temperature for
2 h and quenched by heat denaturation of the proteins in
the presence of Laemmli buffer. The extent of cross-linking
was analysed by sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE). The gel was scanned using
Alpha Imager 2200 software.
LC-ESI mass spectrometry
Recombinant AgTG3 (20 μM) was dialyzed against
HEPES buffer containing 100 mM NaCl, 10 mM CaCl2,
and 5% glycerol. Inhibitors were added to a final concen-
tration of 100 μM and incubated overnight. Samples were
subsequently injected on a Waters ACQUITY Ultraperfor-
mance liquid chromatography (UPLC) system coupled to
an ACQUITY UPLC Photodiode Array (PDA) λ de-
tector. Electrospray ionization (ESI) mass spectrograms
were collected in the positive ion mode and subse-
quently transformed for molecular weight determin-
ation using MASSLYNX software (Waters).
Tandem MS/MS mass spectrometry
Samples prepared for ESI-MS (50 μL) were pretreated
with 2 μL of 10 g/l trypsin (Sigma) for 1 h at 37°C. The re-
action was stopped by formic acid, and the sample was
submitted to the W.M. Keck Biotechnology Resource La-
boratory (Yale University) for tandem MS/MS proteomics
analysis. Results were further analysed using the online
MassMatrix server.
Cysteine protease inhibition assay
The activity of caspase-1 was determined by use of
chromogenic substrate Ac-YVAD-pNA (Enzo Life Sciences,
NY, USA). The assay was performed by adding 45 μLo f1
Unit caspase-1 (Abcam, MA, USA) and 5 μLo fA c - Y V A D -
pNA (final concentration, 5 μM) to 50 μL assay buffer
( 5 0m MH E P E Sp H7 . 4 ,1 0m MD T T ,1m ME D T A ,0 . 1 %
CHAPS, 20% glycerol). Substrate cleavage after 1 h incuba-
tion at 37°C was measured by p-nitrophenyl acetate absorb-
ance at 400 nm in a benchtop UV/Vis spectrophotometer
(UV1800, Shimadzu, Kyoto, Japan).
The activity of recombinant tobacco etch virus (TEV)
protease was determined by cleavage of a fusion protein
containing a TEV cleavage site between GST and a 17 kDa
fragment of human gp78. TEV and GST-gp78 were incu-
bated at 37°C for 10 min at a substrate:enzyme mass ratio
of 10:1. The reaction was stopped by adding 3× loading
buffer (150 mM Tris–HCl pH 6.8, 300 mM DTT, 6% (w/v)
SDS, 0.06% (w/v) bromophenol blue, 30% (v/v) glycerol).
Samples were heated at 95°C for 3 min and separated by
4–20% gradient SDS-PAGE.
Anopheles gambiae laboratory mating assays
Anopheles gambiae G3 strain mosquitoes from a la-
boratory colony were reared using standard conditions
(26–28°C, 65–80% relative humidity, 12 h/12 h Light/
Darkness (L:D) photoperiod). Mosquitoes were sexed
as pupae and adult males and females were allowed to
emerge in separate cages to ensure their status as vir-
gins. Three-day-old virgin males were injected with
138 nl of 100 μM of inhibitor diluted in 5% DMSO, or
with 138 nl of a 5% DMSO solution as a control. Mat-
ing experiments were performed four days after eclo-
sion as described previously and couples were captured
in copula [58]. RNAi experiments were performed as
previously described [39]. Mated females were dis-
sected within two hours of mating to determine the
presence of the mating plug in their atrium.
Results
Primary screening results
The targeted chemical library was screened for inhib-
ition of AgTG3 at 100 μM in a FITC-CAD plate assay
(Figure 3A), performed in triplicate as previously de-
scribed [50]. Hit-calling was based on >67% decrease in
fluorescence compared to DMSO and z >5.Sevencom-
pounds fulfilled these criteria in the primary assay. All were
DHI inhibitors; neither acylidene oxoindoles nor the thie-
nopyrimidinone LD-217912 showed any inhibition of
AgTG3. Of the seven hits, the three most potent had a
common structure (Figure 3B), quinolin-3-ylmethyl (S)-1-
(((S)-3-bromo-4,5-dihydroisoxazol-5-yl)methylamino)-3-(5-
R-1H-indol-3-yl)-1-oxopropan-2-yl-carbamate (Figure 3B),
R=F( 1), OH (2), H (3). Compounds 1–3 are also specific
human TG2 inhibitors [50,51], which suggests a similar
binding site exists for these inhibitors in the active site of
AgTG3 and hTG2.
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sponse curves in the range of 0.5–100 μM were determined
for 27 structurally related compounds within the targeted
library (Additional file 3: Table S2 and Additional file 4:
Table S3). The IC50 for 1–3 were 3.1 μM, 4.3 μMa n d
6.1 μM, respectively. Selected stereoisomers present in the
targeted library were compared in equivalent dose–re-
sponse assays. Inhibition of AgTG3 was specific for the (S)-
DHI isomer of 1 (Figure 4A), the (R)i s o m e r( 4) displaying
no activity (IC50> 100 μM). Substitution of L-phenylalanine
(5) for L-5-fluoro-tryptophan decreased activity (IC50=
29 μM), but the corresponding D-phenylalanine (6) was in-
active (Figure 4B). Hence AgTG3 inhibition is specific
to (S)-DHI and L-amino acid isomers within the DHI
inhibitor library, consistent with the known SAR for
human TG2.
The decreased activity of phenylalanine over tryptophan
suggests the AgTG3 binding pocket has some selectivity
for the amino acid directly conjugated to the DHI war-
head. To examine this question dose–response curves of
aromatic amino acid derivatives of the 3-quinolinylmethyl
carbamate S-DHI inhibitor were compared (Figure 5).
Compounds with indole or benzothiophene derivatives
had lower IC50 values compared to phenyl or napthyl de-
rivatives, implying a preference for a 5-membered versus
6-membered ring in the side chain. 2-fluorophenylalanine
(8) had a similar activity (IC50~3 0 μM) compared to
phenylalanine (5), but 4-fluorophenylalanine and tyrosine
were less active (IC50~65 μM) and 4-iodophenylalanine
was inactive at 100 μM.
Due to the limited size of the compound library, only a
small comparison set exists for different carbamate deriva-
tives of compound 1 (Figure 6). Both quinoxalin-2-ylmethyl
carbamate (12,I C 50 9.7 μM) and quinolin-4-ylmethyl car-
bamate (13,I C 50 12.2 μM) were AgTG3 inhibitors though
slightly less active than compound 1.S u b s t i t u t i o no f
quinolin-3-ylmethyl with tert-butyl carbamate (14)l e dt oa
significantly less active compound (IC50 56 μM), compar-
able to substitution of tyrosine as the amino acid (10)H o w -
ever, substituting the quinolin-3ylmethyl carbamate of 10
with either benzyl or fluorenylmethyl carbamate produced
compounds with no activity at 100 μM.
Figure 3 Primary assay results for AgTG3 inhibitor screen. (A) FITC-CAD/plugin-C cross-linking by AgTG3 incubated with 92 TG2 inhibitors,
iodoacetamide and DMSO control (black), sorted by fluorescent intensity (arbitrary units). Hits shown in white. (inset) Expanded axes for
compounds with I<DMSO, with error. (B) Common chemical structure of top three hits in primary assay.
Le et al. Malaria Journal 2014, 13:210 Page 5 of 12
http://www.malariajournal.com/content/13/1/210Secondary in vitro assays of AgTG3 inhibitors
Additional assays were performed to examine whether
compounds 1 and 3 would inhibit the cross-linking of
plugin-C by AgTG3 in solution, with FITC-CAD for
fluorescent detection of plugin-C. Results were assessed
by SDS/PAGE and UV illumination to detect FITC-CAD
Figure 4 Stereospecificity of AgTG3 inhibitors. (A) Dose–response curves for 1 (S) and the corresponding (R)-DHI isomer (4). (B) Dose–response
curves for the L-phenylalanine derivative of 1 (5) and the corresponding D-phenylalanine derivative (6). The structure of the carbamate substituent is
quinolin-3-ylmethyl formate.
Figure 5 IC50 of aromatic amino acyl side chains. Figure 6 IC50 of carbamate substituents.
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and plugin in the absence of calcium (lanes 1–3) since
TGs are Ca
2+-dependent enzymes. In the presence of
enzyme, substrate and calcium a ladder of fluorescent
bands of increasing molecular weight (MW) is observed
(lane 4), corresponding to cross-linked oligomers of plu-
gin also labeled by FITC-CAD. Cross-linking is inhibited
by both EDTA (lane 5), which chelates calcium, and IA
(lane 6), which blocks the active site cysteine. Com-
pound 1 (lane 7) and, to a lesser extent, 3 (lane 8) inhib-
ited the cross-linking of plugin as evidenced by reduced
intensity of high MW bands. The fact that bands were
observed at all, however, shows that inhibition was not
as complete as for EDTA or iodoacetamide. However,
the levels of AgTG3 in solution assays are higher in the
cross-linking assay than the primary screen. The levels
of plugin-C were also higher, which competes with slow-
binding irreversible inhibitors such as 1 and 3 for the ac-
tive site of AgTG3.
DHI inhibitors form a thioether bond with the TG active
site cysteine [34], a modification that should be detectable
by mass spectrometry. Since 3 appeared less effective in a
solution cross-linking assay than the primary assay, it is
necessary to confirm covalent modification of the active
site cysteine. AgTG3 was treated with 100 μM 3 overnight
and the intact protein subsequently analyzed by ESI-MS
(Figure 8A). The parent mass for unmodified AgTG3 was
detected at m/z=84173 Da. Following overnight treat-
ment with 3, the parent mass was significantly reduced
and a new mass detected at m/z=84638 Da. The +465m/
z shift strongly suggested specific modification of AgTG3.
The expected m/z shift for reaction with 3 is +470, how-
ever, +5 amu than what was observed. To confirm the
mass shift corresponds to modification of the active site
cysteine with 3, treated AgTG3 was subjected to tryptic
digestion and LC-MS/MS analysis. A +469 amu mass shift
of the tryptic peptide containing the AgTG3 active site
cysteine (Cys 323) was detected, with y ion fragmentation
confirming specific modification of Cys 323 (Figure 8B).
No other modified cysteines were detected in the protein.
Taken together, the secondary in vitro assays of cross-
linking and covalent modification confirm 1–3 as active
site inhibitors of AgTG3.
Lack of inhibition of cysteine proteases
Transglutaminases and cysteine proteases have a similar
catalytic mechanism involving an active site cysteine and
formation of a thioacyl intermediate. Hence, inhibitors 1–
3 may not be selective for AgTG3 but also inhibit cysteine
proteases. To test this hypothesis, the inhibition of two
cysteine proteases, human caspase-1 and recombinant to-
bacco etch virus (TEV) protease by 3 at 100 μMw e r e
tested using a chromogenic and SDS-PAGE assay, respect-
ively (Figure 9). In both cases, the DHI inhibitor showed
no inhibition of the protease compared to a DMSO con-
trol, while IA was a potent inhibitor of the enzyme. Nei-
ther human caspase-1 nor TEV are endogenous proteins
in A. gambiae, which may well contain other endogenous
targets of 1–3, not least the two other transglutaminases
in the A. gambiae genome. Nevertheless, the data suggests
that 1–3 are not broad-spectrum inhibitors of cysteine-
containing enzymes.
Inhibition of mating plug formation
Finally, A. gambiae laboratory mating assays were per-
formed to test if the DHI inhibitors identified in the pilot
screen could inhibit male transfer of the mating plug.
Compound 3, 100 μM in DMSO, was administered to
male mosquitoes by intrathoracic injection. Injected males
were mated with virgin females, and their ability to trans-
fer a mating plug to females was assessed (Table 1). In
three independent experiments, 11 out of 75 females
(15%) mated to DHI-injected males failed to receive a
mating plug, compared to 2 out of 59 (3%) females mated
to males injected with DMSO. The fraction of DHI-
treated males that failed to transfer a mating plug is com-
parable to that previously observed for RNAi-mediated
knock-down of AgTG3 [39]. In simultaneous experiments
using dsAgTG3 and dsLacZ, 5 of 77 (7%) females mated to
dsAgTG3-injected males failed to receive a plug, compared
to only 2 of 119 (2%) females mated to dsLacZ-injected
mosquitoes. Thus, injection of males with AgTG3 inhibi-
tor 3 is at least as effective as injection of dsRNA to inhibit
mating plug formation in A. gambiae males.
Figure 7 Inhibition of plugin cross-linking by DHI inhibitors.
Fluorescent image of SDS-PAGE for FITC-cadaverine labeling and
cross-linking of plugin by AgTG3. Lanes (1–4): (1) AgTG3, (2) Plugin-C,
(3) AgTG3 and plugin-C, (4) AgTG3, plugin-C, and 5 mM CaCl2.L a n e s
(5–8): AgTG3, plugin-C, 5 mM CaCl2 and (5) 10 mM EDTA, (6) 50 mM IA,
(7) 100 μM 1, (8) 100 μM 3. (below) Coomassie stain indicating relative
levels of monomeric Plugin-C.
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A number of DHI inhibitors of the A. gambiae male
seminal transglutaminase AgTG3 have been identified
through a targeted pilot screen. The best inhibitors
identified (1–3) are also potent inhibitors of human
TG2. This suggests that the inhibitor may adopt a
similar conformation in the active site in the enzyme.
Indeed, while AgTG3 is only ~30% identical in se-
quence to mammalian transglutaminases the homology
within the active site is significantly higher. No crystal
structure of a TG in complex with a DHI inhibitor is
available, but the structure of TG2 in complex with a
peptidomimetic inhibitor is known [59]. A homology
model of AgTG3 based on the structure of the TG2-
inhibitor complex illustrates the conservation of aro-
matic and Asn residues that surround the active site
cysteine (Figure 10A), supporting the hypothesis of a
common binding pose for the inhibitor.
Figure 8 Covalent modification of AgTG3 by DHI inhibitors. (A) ESI-MS mass spectrum of AgTG3 incubated with 3 (solid line) vs. unmodified
(dashed line). Inset: expanded mass spectrum for unmodified AgTG3. (B) Ion fragmentation spectrum AgTG3 tryptic peptide containing active site
cysteine modified by 3 (m/z 2287.87).
Figure 9 DHI inhibitor inactive for two cysteine proteases. Cleavage of (A) Ac-YVAD-pNA by caspase-I, or (B) GST-gp78 fusion protein by TEV,
in the presence of TG inhibitors: (i) –ve control (DMSO), (ii) 3 (DHI), (iii) iodoacetamide (IA).
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which the Oγ is H-bonded to Trp 288 and Gln 322, the
quinolinyl- and indole moieties of (1–3) could bind
within the common peptide binding groove for both en-
zymes. There are some differences in amino acid resi-
dues within the groove that may present opportunities
for improvement in the affinity and selectivity of AgTG3
inhibitors. Recent structures of fXIIIa in the active con-
formation provide a second starting point for modeling
Table 1 Anopheles gambiae laboratory mating assay
3*** DMSO dsAgTG3* dsLacZ
N 75 59 77 117
Mating plug transferred 64 57 72 119
No plug transferred 11 2 5 2
*p < 0.05 for a cumulative binomial test, p(no plug) = 0.034.
***p < 0.001 for a cumulative binomial test, p(no plug)= 0.034.
Figure 10 Model of the AgTG3 active site. (A) Homology model of AgTG3 (yellow) superimposed with TG2-inhibitor complex 2Q3Z (cyan).
Non-conserved AgTG3 residues (K221, P222, T298, Y380) are shown (orange) in comparison to TG2 (blue) in the peptide-binding groove. (B) Proline is
highly enriched at the P−1 relative to Gln in the N-terminal region of Plugin, justifying the bias towards cyclic amino acid variants in the initial library.
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with kinetic, SAR and structural studies may lead to more
potent active site inhibitors of AgTG3. Future optimization
could also include substitution of the DHI functional group
with other cysteine-reactive functionalities [34].
No cyclic amino acid variants of the DHI inhibitor
series displayed any inhibition of AgTG3 in the primary
assay. A bias for cyclic amino acids in the targeted li-
brary was supported by the observation that plugin is
enriched in Pro-Gln-Ile repeats within the N-terminal
low complexity region (Figure 10B) [42]. The lack of ac-
tivity for cyclic DHI inhibitors suggests that P+1 interac-
tions (such as Ile) are important for the affinity of
Plugin cross-linking sites for AgTG3, which is not
reflected in the scaffold of the existing library. Likewise,
neither the eight acylidene oxoindoles tested nor the
thienopyrimidinone LDN-27219 inhibited AgTG3 at
100 μM, despite all having an IC50<1 0 μMf o rh T G 2
[54-56], suggesting the (unknown) binding site on hTG2
for these compounds is not present in AgTG3. For in-
stance, hTG2 has a binding site for GTP, which func-
tions as negative allosteric regulator [61], but this site is
not conserved in AgTG3 [42]. It remains plausible how-
ever, that allosteric inhibitors of AgTG3 exist, and
present an alternative route toward a more selective
AgTG3 inhibitors.
The observed in vivo efficacy of 3, a 15% reduction in
transfer of the mating plug, is low. Nevertheless, this
r e s u l ti ss i g n i f i c a n ta si tr e p r e s e n t st h ef i r s tr e p o r to f
efficacy for a putative chemosterilant specifically de-
signed to inhibit a seminal fluid protein in a mosquito,
indeed for any insect. The low efficacy observed may
be due to rapid degradation of the compound in the
haemolymph or limited accessibility of the compound
to the male accessory glands (MAGs). Indeed, Cbz-
tryptophan DHI inhibitors have been considered un-
suitable candidates for human drugs due to metabolic in-
stability [50]. Both the carbamate linkage and the amide
bond between the amino acid core are susceptible to
hydrolysis. Hence, the first goal for future synthetic devel-
opment should be substitution or modification of these re-
active bonds while simultaneously improving potency
(IC50) and specificity (kinact/KI) of the inhibitor.
An important caveat to the laboratory mating assay
is that the effect observed may not be a direct effect of
AgTG3 inhibition but an off-target effect of the inhibi-
tor. Anopheles gambiae has two other TGs that may
also be inhibited by compounds 1–3.T h er o l eo ft h e s e
TGs includes haemolymph coagulation and response
to wounding. However, males injected with 3 showed
no obvious ill effect from wounding, suggesting that if
AgTG1 or AgTG2 are inhibited the effect is not sys-
temic. Another concern is reactivity of the carbamate,
especially considering the similarity of quinolinyl-3-
ylmethyl carbamate to existing carbamate insecticides
that target acetylcholinesterase (AChE). Hence, the second
goal for future development of a mechanistic probe of
AgTG3 is (i) develop assays for inhibition of known poten-
tial targets such as AgTG1 and AgTG2, and (ii) validate
that the observed effect in laboratory mating access results
from on-target activity, such as by isolating and analyzing
the activity of endogenous AgTG3 from injected males, or
synthesizing an identical but non-reactive inhibitor (i.e.
lacking the halogen leaving group) as a control compound
for in vivo assays.
A priority for future development is to establish
well-defined criteria that an adequate chemical probe
must meet, based on the broad requirements for a che-
mosterilant [21]. Molecular criteria for bioavailability
of agrochemicals have been proposed based on analysis
of commercially available agents and high-throughput
screening [62], emphasizing low molecular weight
(200–400 amu) and low polarity (logP=3±3) since
topical application is the predominant route of access.
For a laboratory probe molecule however, intrathoracic
injection is a common procedure if a topical or orally
available inhibitor cannot be obtained. Criteria for the
potency, specificity and lifetime of the molecule in vivo
must be empirically established based on the specific
mating experiments, based on the principle that
treated males must display equivalent mating fitness to
untreated males yet a statistically significant defect in
fertility.
While the role of AgTG3 is of specific interest to A.
gambiae, the common role of insect TGs is haemo-
lymph coagulation, cuticle morphogenesis and wound
healing. DmTG knockdown has a pupal semi-lethal
phenotype and abnormal morphology [35], and flies
with reduced TG function show increased mortality
after septic injury, suggesting an immune defect [36].
DmTG knockdown leads to a significant reduction in
lifespan in D. melanogaster adults reared in normal,
but not germ-free, conditions [37]. Interestingly, this
result seems due to decreased immune tolerance to
commensal bacteria rather than the suppression of im-
mune responses to infection. The same function pre-
sumably exists for the conserved TG in mosquitoes
(AgTG1). The role of the second TG shared by Culex
and Anopheles is not clear, but AgTG2 was recently re-
ported to be up-regulated by wounding and involved in
injury-induced immune responses that are cross-
reactive against human malaria [38]. Hence, a second
potential role for TG inhibitors is as immunosuppres-
sants that may act as slow-acting insecticide. Further
study of, and development of inhibitors for, insect TGs
should be pursued with the goal of developing new
strategies to target mosquito fertility and immunity,
for the future control of vector-borne disease.
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